Alliance Global Partners lowered the firm’s price target on GeoVax Labs (GOVX) to $8.50 from $15 and keeps a Buy rating on the shares. The target cut reflects the funding pause of the BARDA Project NextGen and likely halting of the upcoming Phase 2b trial, as well as the general uncertainty related to COVID-19 vaccines going forward, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GOVX: